Biogen announced the widely awaited submission of a U.S. marketing application for the experimental Alzheimer’s therapy aducanumab, sending the company’s shares up more than 8 percent before the bell.
Shares of Sarepta Therapeutics Inc. soared 32 percent after U.S. regulators shocked Wall Street by reversing their rejection of the muscle-wasting disorder therapy less than four months earlier.
Pfizer Inc. reported a higher-than-expected third-quarter 2019 profit on increased sales of the cancer drug Ibrance and a strong launch of the new heart medicine Vyndaqel.
Eli Lilly third-quarter 2019 sales missed Wall Street estimates as rebates limited revenue from the drug manufacturer’s top-selling diabetes medicine Trulicity, and shares fell about 4 percent.
Biogen Inc. revived plans to seek U.S. approval for the experimental Alzheimer’s treatment aducanumab, surprising investors.
Shares of Sarepta Therapeutics Inc. plunged 14 percent after the U.S. health regulator, in an unexpected move, declined to approve the drugmaker’s newest treatment for a muscle-wasting disorder.
The Trump administration took a step toward allowing the importation of medicines from Canada, an action the president has advocated as a way to bring cheaper Rx drugs to Americans.